NCT00412464View on ClinicalTrials.gov

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions
ThrombosisHeparin-induced Thrombocytopenia
Interventions
DRUG

Fondaparinux

Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.

Trial Locations (4)

43205

Nationwide Children's Hospital, Columbus

77030

Texas Children's Hospital, Houston

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

All Listed Sponsors
lead

Children's Hospital Los Angeles

OTHER

NCT00412464 - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis | Biotech Hunter | Biotech Hunter